Enanta Pharmaceuticals to Present at the Deutsche Bank 2014 BioFEST

Presentation to be Webcast on December 1 at 10:25 A.M. ET

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat, or question and answer session, with investors December 1, 2014 at 10:25 a.m. ET during the Deutsche Bank 2014 BioFEST conference in Boston.

A live webcast and replay of the question and answer session can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. The replay webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has a Bicyclolide antibiotic in early clinical development with the National Institute of Allergy and Infectious Diseases (NIAID) for the potential treatment of multi-drug resistant bacterial infections.

Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli, [e-mail]